Endonovo Therapeutics, Inc. SEC filings ENDV

Endonovo Therapeutics, Inc. has 502 filings in SEC EDGAR's recent list, going back to Sep 22, 2011. Its latest annual report, Form 10-K, was filed on Apr 17, 2023 for the period ended Dec 31, 2022. The latest quarterly report (Form 10-Q) was filed on Dec 29, 2023, covering the quarter ended Sep 30, 2023. The most recent current report (Form 8-K) was filed on Jan 3, 2024 (material agreement). The company's fiscal year ends on December 31.

Endonovo Therapeutics, Inc. SEC filings
Form Description Filed Period
424B3 Prospectus Jul 16, 2020 —
S-1/A Amended registration statement Jul 10, 2020 —
S-1 Registration statement Jun 23, 2020 —
POS AM Filing Jun 2, 2020 —
S-1/A Amended registration statement Jan 8, 2019 —
S-1 Registration statement Jan 7, 2019 —
424B3 Prospectus Oct 19, 2016 —
S-1/A Amended registration statement Oct 17, 2016 —
S-1/A Amended registration statement Oct 6, 2016 —
S-1 Registration statement Aug 29, 2016 —
POS AM Endv pos am 03/11/16 Mar 11, 2016 —
S-1/A Amended registration statement Apr 30, 2015 —
S-1/A Amended registration statement Apr 24, 2015 —
S-1 Registration statement Feb 13, 2015 —
424B3 Prospectus Dec 28, 2011 —
S-1/A Amended registration statement Nov 14, 2011 —
S-1 Registration statement Sep 22, 2011 —

Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as
ENDV (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Woodland Hills, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1528172
Former names
Hanover Portfolio Acquisitions, Inc. (until Jan 24, 2014)

Other Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.